64 results
Page 2 of 4
424B5
pdvwmdfk3xp7e
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
EX-1.1
izk6k
16 Jul 21
Entry into a Material Definitive Agreement
4:14pm
424B5
vvf2x2y
16 Jul 21
Prospectus supplement for primary offering
4:07pm
8-K
EX-10.1
4nv8be9pfiyla5t66x8h
13 Nov 20
Termination of a Material Definitive Agreement
4:02pm
8-K
EX-1.1
efpuo2
26 Jun 20
Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock
4:31pm
424B5
cr6gp2 hdnc2ck8
25 Jun 20
Prospectus supplement for primary offering
4:01pm
424B5
ek5pj6yh o6b66xx0
23 Jun 20
Prospectus supplement for primary offering
4:06pm
8-K
EX-99.1
97gfm rgrjc
6 Jan 20
Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome
5:01pm
8-K
EX-1.1
bd9zmzr6mtov5r
25 Oct 19
Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock
4:03pm
424B5
20p yisgct3th
25 Oct 19
Prospectus supplement for primary offering
12:00am
424B5
scdtgh ad5p36d
22 Oct 19
Prospectus supplement for primary offering
4:24pm
S-3
o5vec
11 Jun 19
Shelf registration
5:05pm
424B3
7d65s xie3tgvhc
12 Apr 19
Prospectus supplement
4:41pm